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Abstract
Objectives
To assess whether patients’ willingness to add a blood pressure-lowering drug and the
importance they attach to specific treatment characteristics differ among age groups in
patients with type 2 diabetes.
Materials and Methods
Patients being prescribed at least an oral glucose-lowering and a blood pressure-lowering
drug completed a questionnaire including a discrete choice experiment. This experiment
contained choice sets with hypothetical blood pressure-lowering drugs and a no additional
drug alternative, which differed in their characteristics (i.e. effects and intake moments). Dif-
ferences in willingness to add a drug were compared between patients <75 years (non-
aged) and75 years (aged) using Pearson χ2-tests. Multinomial logit models were used to
assess and compare the importance attached to the characteristics.
Results
Of the 161 patients who completed the questionnaire, 151 (72%) could be included in the
analyses (mean age 68 years; 42% female). Aged patients were less willing to add a drug
than non-aged patients (67% versus 84% respectively; P = 0.017). In both age groups, the
effect on blood pressure was most important for choosing a drug, followed by the risk of
adverse drug events and the risk of death. The effect on limitations due to stroke was only
significant in the non-aged group. The effect on blood pressure was slightly more important
in the non-aged than the aged group (P = 0.043).
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Conclusions
Aged patients appear less willing to add a preventive drug than non-aged patients. The
importance attached to various treatment characteristics does not seem to differ much
among age groups.
Introduction
There is growing interest to tailor drug treatment to the individual patient's clinical and personal
needs. In general, the incorporation of patient preferences in treatment decisions is high on the
agenda in our society. Particularly in drug treatment it is important to take patient preferences
into account since such preferences are related to a patient’s willingness to take a drug. The will-
ingness to take a drug improves adherence and leads to a more effective treatment [1–3].
A patient’s willingness to take a drug is influenced by factors related to the drug, the physi-
cian, the disease, and patient’s own characteristics [4–7]. Drug-related factors include expected
effects on, for example, life extension or factors related to quality of life, such as good health,
ease of taking the drug and burden of adverse drug events (ADEs) [1]. Patients often value life
extension as one of the most important drug effects [8–11]. On the other hand, many aged or
frail patients are likely to value quality of life over life extension [12–14]. Therefore, one may
expect that preferences for specific drugs and the willingness to add a treatment are influenced
by a patient’s age or life-expectancy, as has been shown previously [12,15,16].
The role of patient’s age on drug choices may be particularly important for preventive treat-
ment, such as the use of blood pressure-lowering drugs in patients with type 2 diabetes to
reduce their risk for cardiovascular morbidity and mortality [17]. With respect to balancing life
extension with quality of life, the need for blood pressure-lowering drugs may be less in aged
patients since 1) evidence of long-term benefit in aged patients is lacking [18], 2) having a high
blood pressure level is usually not perceived as burdensome [19], and 3) adverse events related
to these drugs are common in the aged [20,21]. In general, patients with type 2 diabetes appear
to have lower necessity beliefs for blood pressure-lowering drugs than, for instance, for glu-
cose-lowering drugs [19,22]. Currently, little is known about preferences for choosing blood
pressure-lowering treatment among aged and non-aged patients.
A useful and commonly used method to assess patient preferences for treatment is the dis-
crete choice experiment [23,24]. In such experiments, a hypothetical situation is presented to
the patient with treatment alternatives described by their characteristics, or so-called attributes
[25]. The relative importance of the attributes can be inferred from the choices made [26]. This
method is useful because people have to make trade-offs between positive and negative conse-
quences of a choice, similar to decisions that they have to make in practice.
The aim of this study is to assess whether patients’ willingness to add a blood pressure-low-
ering drug and the importance they attach to specific treatment characteristics differ among
age groups in patients with type 2 diabetes.
Materials and Methods
Study design and participants
This study was conducted in 2014 and has a cross-sectional design in which we compared
patients<75 years with75 years of age. Patients were eligible to participate when they were
aged18 years and had been prescribed at least an oral glucose-lowering and a blood
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pressure-lowering drug in the past 6 months. We aimed to include 150 patients in our study,
since it has been shown that the precision of discrete choice experiments rapidly decreases at
sample sizes less than 150 [26]. Pharmacists in the northern part of the Netherlands sent invita-
tion letters to eligible patients identified from their electronic records. Patients who gave writ-
ten informed consent received a questionnaire including general questions such as Cantril’s
ladder to assess a patient’s quality of life [27], and subsequently the discrete choice experiment
to evaluate their treatment preferences. Patients were called when they did not return the ques-
tionnaire within two months or in case of missing data in the general questions. In case of miss-
ing data in the discrete choice experiment, the questionnaire was returned to the patient for
further completion. The Medical Ethics Committee of the University Medical Center Gro-
ningen (METc UMCG) in the Netherlands determined that ethical approval was not needed
for this study (reference number M14.150721). The study was carried out in accordance with
the Code of Ethics of the World Medication Association (Declaration of Helsinki) for experi-
ments involving humans.
Outcome variable
The outcome variable in this study was the choice patients made in a hypothetical situation
with respect to adding a blood pressure-lowering drug.
Discrete choice experiment
Attributes in the discrete choice experiment were based on a two-step literature review. In the
first step, the literature was assessed for factors which may influence a patient’s willingness to
take blood pressure-lowering drugs or drugs for primary cardiovascular disease prevention in
general. This review revealed that lowering the blood pressure, achieving risk reduction of
complications (myocardial infarction, stroke), reducing ADEs and improving quality of life
were relevant factors [4–7]. During the second step, previous studies with discrete choice
experiments to assess patient preferences for any drug were screened. This screening revealed
two additional attributes, that is, costs of treatment and number of tablets needed per day [28–
35]. We decided not to include costs in our experiment since expenditure for preventive drugs,
such as blood pressure-lowering drugs, are covered by the health insurance in the Netherlands.
Levels of efficacy were established using clinical trial data of blood pressure-lowering treat-
ment effects and cardiovascular risk reduction between tight and less tight blood pressure con-
trol, and using the UKPDS risk engine for assessing differences among different ages [36]. We
estimated risks of complications or death within the next 5 years. Levels for ADEs were based
on the prevalence of known ADEs for blood pressure-lowering drugs, such as cough and head-
ache, as reported in the national drug compendium for healthcare professionals. Levels for the
intake moments were based on possible schemes mentioned in the literature [37,38]. The list of
attributes and levels was discussed and finalized by interviews with ten experts (2 nurse practi-
tioners, 3 general practitioners, 2 specialists, and 3 pharmacists) (Table 1).
A d-efficient design [26] of 30 choice sets, divided in three blocks, was generated using
Ngene (version 1.1.1). No restrictions of level combinations were included. Patients were ran-
domly assigned to one of the blocks containing ten choice sets. This blocking was used to
reduce the cognitive burden of the patients. Patients had to imagine that they were using one
blood pressure-lowering drug and that their blood pressure was uncontrolled (160 mmHg). In
the choice sets, patients could indicate how they would want to continue their treatment,
choosing from hypothetical treatment options presented as ‘no additional drug’, ‘additional
drug A’, or ‘additional drug B’. The profile of ‘no additional drug’ described the situation as
presented in the case, whereas the profiles of ‘additional drug A’ and ‘additional drug B’ were
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generated with the d-efficient design. Patients were asked to complete the ten choice sets plus a
choice set in which one drug was preferable on all attributes compared to the other drug. This
dominant choice set was added to identify the responders who may not understand the task.
A pilot study was conducted in which ten patients with type 2 diabetes completed the full ques-
tionnaire. Based on this pilot study, minor changes in wordings were made and a separate instruc-
tion form for the choice sets was included. An example of a final choice set is presented in Fig 1.
Patients’ age and life-expectancy
In the questionnaire, patients were asked their age. We used a cut-off level of75 years to
define aged patients. This cut-off level has been used in guidelines [39] and observational stud-
ies [40] looking at age differences for preventive treatment. To test its value in relation to per-
ceived life-expectancy, we additionally asked patients an open-ended question: “In 2012, men
became on average 75 years old and women on average 80 years old [41]. How old do you
think you will become?”. With this we determined that age was a reasonable proxy for self-
reported life-expectancy (S1 Table).
Additional data collection
Pharmacists provided the age and gender for all eligible patients, as well as overviews of pre-
scribed drugs in the last six months for those patients who gave written informed consent. The
Table 1. Overview of the attributes and levels used in the discrete choice experiment.
Attributes Levels Coding
Blood pressure level1 Remains 160* 160
Decrease from 160 to 140 140
Decrease from 160 to 150‡ 150
Risk of death by a heart attack or stroke in the next 5 years1 13 of the 100 die and 87 don’t* 0.13
9 of the 100 die and 91 don’t 0.09
11 of the 100 die and 89 don’t‡ 0.11
Risk of limitations due to a heart attack, such as fatigue and difﬁculty
walking in the next 5 years1
7 of the 100 get limitations and 93 don’t* 0.07
5 of the 100 get limitations and 95 don’t 0.05
6 of the 100 get limitations and 94 don’t‡ 0.06
Risk of limitations due to a stroke, such a speech problems and
forgetfulness in the next 5 years1
7 of the 100 get limitations and 93 don’t* 0.07
5 of the 100 get limitations and 95 don’t 0.05
6 of the 100 get limitations and 94 don’t ‡ 0.06
Risk of side effect3, such as cough and headache1 No side effects* 0
5 of the 100 get side effects and 95 don’t 0.05
10 of the 100 get side effects and 90 don’t‡ 0.10
Intake moment2 1 tablet in the morning* -
1 tablet in the morning and 1 in the evening‡
1 combination tablet
2 tablets in the morning†
1 Continuous variable;
2 Categorical variable;
3 Side effect used as lay-term for adverse drug events.
* Level used for ‘no additional drug’ option (never used for the additional drug options).
‡ Levels used for the non-preferable drug in the dominant choice set.
† Reference category in the categorical attribute.
doi:10.1371/journal.pone.0139755.t001
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Fig 1. Example of a choice set presented in the questionnaire.
doi:10.1371/journal.pone.0139755.g001
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Anatomical Therapeutic Chemical (ATC) classification system of the World Health Organiza-
tion was used to classify the prescribed drugs.
Statistical analyses
Descriptive statistics are presented for patient characteristics. Differences in age and gender
between patients who completed the study and those who did not participate or complete the
study were assessed using the T-test and Pearson χ2-test respectively. Differences in character-
istics between non-aged and aged patients were tested using Pearson χ2-tests for categorical
variables and Mann-Whitney U tests for non-normally distributed, continuous variables. The
Fisher freeman-halton test was used for categorical variables in which one or more cells con-
tained less than five patients.
Differences in the number of patients who chose at least once an additional drug on the
choice sets (willing to add) versus never (unwilling to add) were compared between the age
groups using the Pearson χ2-test. The choices were further analysed using multinomial logit
models (asclogit function in Stata) to assess 1) the willingness to add a blood pressure-lowering
drug when controlling for all attributes, and 2) the relative importance of the attributes. Four
models were assessed, that is, one including all patients, one including non-aged patients, one
including aged patients, and one with all patients in which the interaction terms between these
two age groups and the attributes were included.
We followed the random utility model by assuming that patients choose the alternative in
each choice set which maximizes their utility. The estimated model was the following:
U ¼ V þ ε
¼ b0additional drug þ b1blood pressureþ b2deathþ b3limitations heart attackþ
b4limitations strokeþ b5ADEsþ b6one in morning one in eveningþ
b7combination tabletþ ε
with U indicating the utility that a patient assigns to a treatment which is the sum of a system-
atic, explainable component V and a random, unexplainable component ε. The explainable
component is a function of the attributes of the alternatives. The constant β0 indicates the rel-
ative weight patients place on choosing an additional blood pressure-lowering drug versus no
additional blood pressure-lowering drug when controlling for the attributes. The β1 to β7
coefﬁcients indicate the relative importance of each of the attributes. Coefﬁcients reﬂect con-
tinuous variables of the attributes, except β6 and β7 which reﬂect the dummy-coding of
respectively the level one drug in the morning and one in the evening (coded as 1) versus two
drugs in the morning (coded as 0), and the level combination tablet (coded as 1) versus two
drugs in the morning (coded as 0). The sign of the beta-coefﬁcients indicates whether the
effect on the utility is positive or negative. Attributes with beta-coefﬁcients with a two-sided
P-value<0.05 were considered as being important for the treatment choice. Important attri-
butes were ranked according to their relative importance. This was determined by calculating
the difference between the smallest part worth utility and the largest part-worth utility of the
levels of an attribute, and dividing this difference by the sum of the difference scores for all
attributes [42].
Patients who chose the non-preferable drug in the dominant choice set were excluded from
the analyses. Sensitivity analyses were conducted in which these patients were not excluded.
Additional sensitivity analyses were conducted to assess the multinomial logit model for
patients<65 years and patients aged80 years. The analyses were conducted using Stata ver-
sion 13 (Stata Corp., College Station, TX).
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Results
Three pharmacies sent information letters to 933 patients, resulting in 210 eligible consenting
patients. Of these, 161 completed the questionnaire (Fig 2). There was no significant age differ-
ence between these completers and the non-completers (69 and 69 years, P = 0.310), but less
females completed the study (42% versus 52% females, P = 0.025). This difference became
insignificant in an additional analysis per age group (data not shown). In the final analyses, 151
were included. The included patients were on average 68 ± 9 yrs and the majority were males
(58%). Metformin was the most commonly prescribed glucose-lowering drug in both aged and
Fig 2. Patient inclusion flow-chart.
doi:10.1371/journal.pone.0139755.g002
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non-aged patients (Table 2). Agents acting on the renin-angiotensin system (RAS-inhibitors)
were the most commonly prescribed blood pressure-lowering drug class in non-aged patients,
whereas the β-blockers were the most commonly prescribed class in aged patients. Most of the
patients reported that their blood pressure was<160 mmHg, that they used one or two drugs
to lower their blood pressure, and that they preferred to leave decisions about their drugs to the
general practitioner (Table 2).
Influence of age on willingness to add a blood pressure-lowering drug
Of the aged patients, 67% chose an additional drug in at least one of the ten presented choice
sets. This percentage was significantly lower than in non-aged patients (84%; P = 0.017). The
same is reflected in the drug choice model where the constant is more negative in the aged than
in the non-aged (Table 3).
Influence of age on importance attached to drug attributes
Drug attributes that significantly influenced the choices for an additional blood pressure-low-
ering drug in the total group were the effect on the blood pressure, the risk of experiencing
ADEs, the risk of death within the next 5 years, and the risk on limitations due to stroke within
the next 5 years (Table 3). These results were similar in the analyses including only non-aged
patients. The risk of limitations due to a stroke within the next 5 years did not significantly
contribute to the choice of an additional drug in the aged group. Ranking of the relative impor-
tance of the attributes revealed that in both aged and non-aged patients, the effect on the blood
pressure was the most influencing attribute, followed by the risk of experiencing ADEs and the
risk of death within the next 5 years (Table 3).
A sensitivity analysis in which the patients who failed the dominant choice set were
included, revealed similar results (S2 Table). In addition, sensitivity analyses including only
younger patients (<65 years) or older patients (80 years) showed the same direction for all
coefficients but some coefficients became insignificant (S3 Table).
Only the impact of the blood pressure-lowering effect turned out to be significantly different
among the age groups (Table 3, interaction, P = 0.043). This finding indicates that the effect of
an additional drug on the blood pressure level was seen as more important by non-aged
patients than aged patients.
Discussion
This study in patients with type 2 diabetes shows that aged patients were less willing to add a
blood pressure-lowering drug than non-aged patients when they had to imagine that their
blood pressure was too high. The effect of a drug on the blood pressure was more important
for non-aged patients than aged patients. The effects on the risk of death within the next 5
years and experiencing ADEs were important drug characteristics for choosing a drug in both
age groups. For non-aged patients, also the risk of limitations due to a stroke was important.
Previously, it was found that patients with a limited life-expectancy have a decreased will-
ingness to add treatment because they may value quality of life over life extension [12,15]. On
the other hand, it was also found that a large proportion of such patients remain willing to
undergo burdensome treatment for a small risk reduction of death [12]. Our study confirms
the finding that aged patients are less willing to add a drug than non-aged patients. The finding
that the drug effect on reducing the risk of death within the next 5 years was of similar impor-
tance for aged and non-aged patients may be surprising, but fits with the finding that many
aged patients remain willing to undergo burdensome treatment for a risk reduction of death
Preferences for Blood Pressure-Lowering Drugs
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Table 2. Patient characteristics per age group.
Characteristic All <75
years
75
years
P-
value
Included patients 151 106 45
Mean age (SD) 68 (9.2) 64 (7.1) 79 (3.6)
Females (%) 64 (42.4) 40 (37.7) 24 (53.3) 0.0761
Median body mass index (IQR) 28 (26–
32)
29 (27–
33)
26 (24–
29)
0.0002
Education (%) 0.4723
Lower educationa 86 (57.0) 59 (55.7) 27 (60.0)
Middle educationb 44 (29.1) 34 (32.1) 10 (22.2)
Higher educationc 17 (11.3) 11 (10.4) 6 (13.3)
Other 4 (2.7) 2 (1.9) 2 (4.4)
Smoking 0.0111
Current smokers 22 (14.6) 16 (15.1) 6 (13.3)
Past smokers 75 (49.7) 60 (56.6) 15 (33.3)
Non smokers 54 (35.8) 30 (28.3) 24 (53.3)
Median quality of life (IQR)◦ 3 (3–5) 3 (3–4) 4 (3–5) 0.3512
Classes of prescribed blood pressure-lowering drugs (ATC code)*
Centrally acting antihypertensives (C02) 2 (1.3) 0 (0.0) 2 (4.4) 0.0893
Diuretics (C03) 49 (32.7) 31 (29.5) 18 (40.0) 0.2101
β-Blockers (C07) 87 (58.0) 56 (53.3) 31 (68.9) 0.0771
Calcium channel blockers (C08) 33 (22.0) 20 (19.1) 13 (28.9) 0.1821
Agents acting on the renin-angiotensin system (C09) 104
(69.3)
74 (70.5) 30 (66.7) 0.6431
Combination tablet‡ 27 (18.0) 16 (15.2) 11 (24.4) 0.1791
Classes of prescribed glucose-lowering drugs (ATC code)*
Insulin (A10A) 33 (22.0) 27 (25.7) 6 (13.3) 0.0931
Biguanides (metformin) (A10BA) 135
(90.0)
96 (91.4) 39 (86.7) 0.3731
Sulfonamides (A10BB) 58 (38.7) 39 (37.1) 19 (42.2) 0.5581
Combination Metformin and Sulfonamide (A10BD02) 1 (0.7) 1 (1.0) 0 (0.0) 1.0003
Thiazolidinediones (A10BG) 1 (0.7) 1 (0.95) 0 (0.0) 1.0003
Dipeptidyl peptidase 4 inhibitors (A10BH) 13 (8.7) 9 (8.6) 4 (8.9) 1.0003
Liraglutide (A10BX07) 2 (1.3) 2 (1.9) 0 (0.0) 1.0003
Use of lipid-lowering drugs (%)* 0.0193
No lipid-lowering drug 27 (18.0) 13 (12.4) 14 (31.1)
1 lipid-lowering drug 117
(78.0)
88 (83.8) 29 (64.4)
2 lipid-lowering drugs 6 (4.0) 4 (3.8) 2 (4.4)
Drug burden expressed as median number of chronic treatments from 8 anatomical chapters (IQR)ø 3 (3–4) 3 (3–4) 4 (3–4) 0.0252
High blood pressure
How serious do you think that having a high blood pressure is in general? (%) 0.5843
Very serious 20 (13.4) 13 (12.4) 7 (15.9)
Reasonable serious 93 (62.4) 69 (65.7) 24 (54.6)
A little serious 28 (18.8) 18 (17.1) 10 (22.7)
Not serious 8 (5.4) 5 (4.8) 3 (6.8)
How high was your systolic blood pressure during the last measurement conducted by your general
practitioner or nurse practitioner? (%)
0.1621
<120 mmHg 10 (6.6) 7 (6.6) 3 (6.7)
(Continued)
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[12]. This might be explained by the fact that the aged group still perceived they had sufficient
life-expectance.
Previous studies have not directly compared the importance attached to various treatment
outcomes between aged and non-aged patients. Our study revealed that most characteristics
were similarly valued by aged patients in comparison to non-aged patients. Both groups
attached a similar importance, for example, to the risk of ADEs, and in both groups was the
effect on the blood pressure ranked as most important attribute. However, the effect on the
blood pressure was the only attribute that significantly differed in importance between aged
and non-aged patients. This finding could imply that aged patients are less willing to add a
blood pressure-lowering drug because they believe that decreasing the blood pressure is of less
importance. Whether this is influenced by the current advise of guidelines, and thus
Table 2. (Continued)
Characteristic All <75
years
75
years
P-
value
120–139 mmHg 66 (43.7) 52 (49.1) 14 (31.1)
140–159 mmHg 47 (31.1) 32 (30.2) 15 (33.3)
160 mmHg 16 (10.6) 9 (8.5) 7 (15.6)
I do not know 12 (8.0) 6 (5.7) 6 (13.3)
Number of patients who report ever having experienced a symptom of high blood pressure (%) 36 (23.8) 25 (23.6) 11 (24.4) 0.9101
Blood pressure-lowering drugs
Number of drugs that the patients report to use for high blood pressure 0.1021
None 6 (4.0) 6 (5.7) 0 (0.0)
One 79 (52.3) 55 (51.9) 24 (53.3)
Two 38 (25.2) 29 (27.4) 9 (20.0)
More than two 19 (12.6) 9 (8.5) 10 (22.2)
I do not know 9 (6.0) 7 (6.6) 2 (4.4)
Have you ever experienced a side effect of a blood pressure-lowering drug 0.5111
No 110
(72.9)
78 (73.6) 32 (71.1)
Yes 24 (15.9) 18 (17.0) 6 (13.3)
I do not know 17 (11.3) 10 (9.4) 7 (15.6)
I prefer to leave decisions about my drugs to my general practitioner† 142
(94.0)
100
(94.3)
42 (93.3) 0.8111
a No education; Elementary school; Junior secondary vocational education.
b Junior general secondary education; Senior secondary vocational education.
c Senior general secondary education; Higher professional education; University education.
SD = Standard deviation; IQR = Interquartile range; ATC = Anatomical Therapeutic Chemical.
◦ Measured with Cantril’s ladder [27] with a range of 1 (best)– 10 (worst possible life).
* N = 150 (medication overview of one patient was not extracted at the time of data collection since the patient had not given written informed consent
yet).
‡ ATC codes: C03EA01, C07BB02, C09BA03, C09BA04, C09BA06, C09BB04, C09DA01, C09DA03, C09DA04, C09DA06, C09DB02.
ø Drug burden was counted at the anatomical ATC level for the chapters: A, B, C, H, L, M, N, R (maximum of 8).
† Statement adapted from [43]. Scored on a 6-point Likert scale and divided by (partially, totally) agree and (partially, totally) disagree. Number is
presented for those who agree.
1 Pearson χ2-test;
2 Mann-Whitney U test;
3 Fisher freeman-halton test.
doi:10.1371/journal.pone.0139755.t002
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practitioners, to take a patient’s age or life-expectancy into account in setting blood pressure
targets [44,45], remains to be determined.
In both age groups, the choice for a blood pressure-lowering drug was not significantly
influenced by the risk reductions in limitations in daily life due to a heart attack. This finding
may be due to a more subjective interpretation of such an attribute compared to an attribute
such as death [46]. However, the preferences of the non-aged patients were influenced by a
similar attribute, that is, the risk of limitations due to a stroke. Therefore, it seems that reducing
potential limitations due to a heart attack from 7% to 5% was not decisive for the patients'
treatment choices, whereas a similar reduction for limitations due to stroke was. These findings
are comparable with a previous study showing that patients are less willing to risk cognitive dis-
ability than physical disability [12]. For the aged patients, however, reducing potential limita-
tions due to a stroke from 7% to 5% was not critical. Possibly, the presented problems, i.e.
speech problems and forgetfulness, may have been perceived by aged patients as an expected
part of aging [47]. Presenting more severe problems, such as becoming dependent on others,
might have increased the relevance of this aspect since maintaining independent is important
for aged patients [48,49].
Table 3. Preferences of all patients and divided in patients aged <75 years (non-aged) and75 years (aged).
Constant
and
attributes
All patientsa <75 yearsb 75 yearsc P-value of the
interaction
between age
groups and
preferencesd
Coefﬁcient
(95% CI)
P-
value
Relative
importance
(ranking)*
Coefﬁcient
(95% CI)
P-
value
Relative
importance
(ranking)*
Coefﬁcient
(95% CI)
P-
value
Relative
importance
(ranking)*
Constant
(additional
drug)
-1.26 (-1.72
–-0.80)
0.000 -1.05 (-1.60
–-0.50)
0.000 -1.65 (-2.52
–-0.77)
0.000 0.257
Blood
pressure
-0.08 (-0.10
–-0.07)
0.000 36.10 (1) -0.09 (-0.11
–-0.08)
0.000 37.22 (1) -0.06 (-0.09
–-0.03)
0.000 36.84 (1) 0.043
Death within
the next 5
years
-22.13
(-28.75
–-15.51)
0.000 19.97 (3) -21.79
(-29.59
–-13.99)
0.000 18.03 (3) -24.43
(-37.32
–-11.54)
0.000 30.00 (3) 0.731
Limitations
heart attack
-9.16
(-22.29–
3.98)
0.172 -9.13
(-24.61–
6.36)
0.248 -11.31
(-36.83–
14.22)
0.385 0.886
Limitations
stroke
-26.65
(-39.89
–-13.41)
0.000 12.03 (4) -30.22
(-45.83
–-14.61)
0.000 12.50 (4) -15.71
(-41.42–
10.00)
0.231 0.344
Adverse drug
events
-14.14
(-16.89
–-11.39)
0.000 31.90 (2) -15.59
(-18.86
–-12.31)
0.000 32.24 (2) -10.80
(-16.02
–-5.58)
0.000 33.16 (2) 0.128
Additional
tablet in the
evening
0.07 (-0.10–
0.25)
0.424 0.13 (-0.08–
0.34)
0.216 -0.10 (-0.44–
0.24)
0.578 0.264
Combination
tablet
0.13 (-0.05–
0.31)
0.151 0.10 (-0.11–
0.31)
0.361 0.21 (-0.12–
0.54)
0.206 0.566
a Number of observations 4,530 (151 patients * 10 choice sets * 3 alternatives per choice set).
b Number of observations 3,180 (106 patients * 10 choice sets * 3 alternatives per choice set).
c Number of observations 1,350 (45 patients * 10 choice sets * 3 alternatives per choice set).
d Interaction between preferences and age groups added to the model of all patients.
* Determined by calculating the difference between the smallest part worth utility and the largest part-worth utility of the levels of an attribute, and dividing
this difference by the sum of the difference scores for all attributes [42].
CI = Conﬁdence interval.
doi:10.1371/journal.pone.0139755.t003
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In our study, patients’ preferences for a blood pressure-lowering drug were not significantly
influenced by the intake moment of the drug. A previous discrete choice experiment in patients
with type 2 diabetes showed that the intake moment influences patient preferences, but that this
is more important for patients who are taking less than five drugs a day compared to patients
with five or more drugs per day [50]. This may explain the non-significant influence of the intake
moment in our study since many patients were prescribed not only glucose-lowering and blood
pressure-lowering drugs but also lipid-lowering drugs and drugs for other chronic diseases.
This study was conducted in the north of the Netherlands, which includes a mostly cauca-
sian population. Selection bias may have occurred since only 17% of the contacted patients
completed the questionnaire and less females completed the study. Regarding age there were
no differences between those who completed the study and those who did not. Although we
reached a sample size of 150 patients, it should be noted that the included number of patients
per age group was lower which may have reduced the efficiency of the models for the separate
groups. This limitation may especially apply to the aged group (75 years) since only 45
patients were included. In the aged group, more blood pressure-lowering drugs and especially
β-blockers were used than in the non-aged group. However, a post-hoc analysis showed that
the reported use of two or more blood pressure-lowering drugs was not associated with less
willingness to add a drug (data not shown). In this study, age seemed to be a reasonable proxy
for life-expectancy. There are also some strengths and limitations to a discrete choice experi-
ment. A major strength is that it comes close to the trade-offs and choices that have to be made
in real life, and can thus provide better estimates of the relative importance of different treat-
ment characteristics than when asking patients to rate the importance of each characteristic
separately. The evaluation of several treatment alternatives and attributes at one time reveals a
rich source of data [26,51]. Moreover, the ‘no additional drug’ option was included which rep-
resents actual choices in practice. However, the choices that have to be made may be complex
and may require high cognitive efforts [52]. Aged patients may have more problems with such
choices than non-aged patients due to increased cognitive impairment. However, an explor-
atory study among older patients showed that cognitive impairment had no significant impact
on the consistency of responses in a discrete choice experiment [53]. Furthermore, hypothetical
situations have to be assessed in discrete choice experiments which do not necessarily represent
actual behaviour [54,55]. Some patients may have difficulty in making hypothetical choices. To
reduce complexity and effort, patients were presented a sample of ten choice sets and a pilot
study in eligible patients was conducted to detect and resolve any difficulties. The pilot study
revealed only a need for minor changes in wording and the use of a separate instruction card,
and indicated that the task was doable for (aged) patients with type 2 diabetes. In addition, we
excluded 10 patients from the analyses who failed the dominant choice set. There is discussion
in the literature about the fairness of excluding such responders [56], but the sensitivity analy-
sis in which these patients were included revealed similar results. A final limitation may be that
for most of the attributes only a reduction in the frequency of a risk was presented. Other infor-
mation may be relevant for patients. For instance, patients may want information about the
severity and duration of the ADEs.
In conclusion, it is important to acknowledge that aged patients may be less willing to add a
blood pressure-lowering drug than non-aged patients. This finding underlines the importance
of discussing patients' preferences even when they prefer to leave the final treatment decision
to their general practitioner. When choosing a drug, aged patients attach as much importance
to reduce their risk of death within the next 5 years and of experiencing ADEs as non-aged
patients. Therefore, treatment decisions in clinical practice should focus on quality of life as
well as life extension in both age groups in which the individual patient’s preferences and will-
ingness to add a drug should be taken into account.
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